Cargando…
Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action
Background and Aims. This study analyzed the risk of clinical trial failure of new drugs for hepatitis C between January 1998 and January 2015. Methods. Hepatitis C drug development trials that were in phases I–III of clinical trial testing were obtained from the publicly accessible clinical trial r...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi Publishing Corporation
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904655/ https://www.ncbi.nlm.nih.gov/pubmed/27446855 http://dx.doi.org/10.1155/2016/6260271 |